Andrew Cleeland

Andrew is the CEO of the Fogarty Institute and is a seasoned executive with 30 years in the medical device industry in both the private and public sectors. Prior to joining the Fogarty Institute, he was vice president and general manager of Medtronic’s (MDT:NYSE) Transcatheter Mitral Valve business following its 2015 acquisition of Twelve Inc., where he was president and CEO. Prior to Twelve, he was president and CEO of Ardian Inc., the pioneer of renal denervation for hypertension, heart failure and other associated disorders, which was also acquired by Medtronic in 2011. He is currently vice chairman of The Foundry, the premier medical device incubator based in Menlo Park, CA. Andrew holds a Bachelor of Applied Science (biophysics) from the Swinburne Institute of Technology.